Pfizer Inc. stock (US7170811035): Q1 2026 results and recent share price move

Pfizer Inc. reports first?quarter 2026 revenues of $14.5 billion and reaffirms full?year 2026 guidance, while its NYSE?listed stock trades down about 3% on Friday.

Pfizer Inc. has reported first?quarter 2026 revenues of $14.5 billion, up 5% year over year, and reaffirmed its full?year 2026 financial guidance, including revenue in a range of $59.5 billion to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00, according to a press release dated May 7, 2026.Biospace as of 05/07/2026

The operational revenue growth of 2% was driven by higher sales of Padcev, Eliquis, oncology biosimilars, Nurtec and several other products, partially offset by lower COVID?19 product revenues, the company said.Biospace as of 05/07/2026

On the equity side, Pfizer Inc. shares traded down about 3.1% on Friday, May 8, 2026, with the stock touching a low of $25.60 and last trading around $25.65 on the New York Stock Exchange, according to a MarketBeat alert published the same day.MarketBeat as of 05/08/2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pfizer Inc.
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: New York, United States
• Core markets: United States, Europe, Asia and other global markets
• Key revenue drivers: Oncology, internal medicine, vaccines, hospital and consumer healthcare products
• Home exchange/listing venue: New York Stock Exchange (ticker: PFE)
• Trading currency: U.S. dollar (USD)

Pfizer Inc.: core business model

Pfizer Inc. operates as a global biopharmaceutical company focused on discovering, developing and commercializing medicines and vaccines across a broad range of therapeutic areas, including oncology, internal medicine, inflammation and immunology, rare diseases and vaccines.Pfizer official site

The company generates revenue through prescription medicines sold to wholesalers, pharmacies and hospitals, as well as through vaccines and consumer?health products distributed via retail and healthcare channels.Pfizer official site

Pfizer also earns income from collaborations, licensing agreements and partnerships with other biotech and pharmaceutical firms, which can include upfront payments, milestone payments and royalties on future sales.Pfizer SEC filings

Main revenue and product drivers for Pfizer Inc.

Among Pfizer’s key products are oncology brands such as Padcev and biosimilar oncology therapies, which contributed to the 2% operational revenue growth in the first quarter of 2026, alongside established medicines like Eliquis and migraine treatment Nurtec.Biospace as of 05/07/2026

Vaccines, including COVID?19 vaccines and other immunization products, remain an important segment, although COVID?19?related revenues have declined compared with earlier pandemic years, reflecting lower demand and changing public?health dynamics.Biospace as of 05/07/2026

Internal medicine and hospital products, as well as consumer?health offerings, also support Pfizer’s diversified revenue base and help mitigate concentration risk in any single therapeutic area or product line.Pfizer official site

Conclusion

Pfizer Inc. delivered first?quarter 2026 revenues of $14.5 billion and maintained its full?year 2026 guidance, highlighting continued demand for its oncology, internal?medicine and vaccine portfolios despite lower COVID?19?related sales.Biospace as of 05/07/2026

At the same time, the stock has recently traded down about 3% on the New York Stock Exchange, reflecting investor sentiment around valuation, competitive dynamics and the evolving post?pandemic environment for vaccine and therapeutic demand.MarketBeat as of 05/08/2026

For US investors, Pfizer offers exposure to a diversified global pharmaceutical portfolio with established brands and a pipeline of new products, but also faces risks from pricing pressure, patent expirations and regulatory scrutiny in key markets.Pfizer SEC filings

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.